Home > Journals > Medicine > Bulletin du cancer > summary
 
      Advanced search    Shopping cart    French version 
 
Latest books
Catalogue/Search
Collections
All journals
Medicine
Bulletin du Cancer
- Current issue
- Archives
- Subscribe
- Order an issue
- More information
Biology and research
Public health
Agronomy and biotech.
My account
Forgotten password?
Online account   activation
Subscribe
Licences IP
- Instructions for use
- Estimate request form
- Licence agreement
Order an issue
Pay-per-view articles
Newsletters
How can I publish?
Journals
Books
Help for advertisers
Foreign rights
Book sales agents



 

Texte intégral de l'article
 
Printable version

Molecular mechanisms of tamoxifen resistance


Bulletin du Cancer. Volume 84, Number 1, 69-75, Janvier 1997, Synthèses

Résumé   Article gratuit  

Author(s) : Nathalie Bachmann-Moisson, Muriel Barberi-Heyob, Jean-Louis Merlin

Summary : Tamoxifen is the most currently used antiestrogen in the endocrine treatment of breast cancer. However, despite a small proportion of estrogen receptor positive tumors presenting de novo resistance to treatment, numerous tumors develop acquired resistance after a first phase of response. Many mechanisms have been proposed, but none could be identified as a real explanation of these phenomena of resistance. The hypotheses suggested are related to the series of events implied in the transduction of the signal following the ligand binding to estrogen receptor and concerning several levels: (1) loss or mutation of the estrogen receptor; (2) modification in estrogen receptor associated parameters; (3) alteration in the estrogen response element; (4) high levels of antiestrogen binding sites; (5) alteration of metabolism or availability of tamoxifen. The tamoxifen resistance certainly concerns several of these mechanisms. Therefore, it is necessary to go on studying these mechanisms and to elucidate the connections existing between all of them.

Keywords : breast cancer, tamoxifen, resistance.

 

About us - Contact us - Conditions of use - Secure payment
Latest news - Conferences
Copyright © 2007 John Libbey Eurotext - All rights reserved
[ Legal information - Powered by Dolomède ]